Jun. 23 at 5:43 AM
$ACTU Only 160 watchers! Consinsus strong buy by analysts even with their financial issues. Why? Because their drug has had very successful phase 2 trials with adults. More results coming this year.
How do they keep funding? Actuate officially established a
$100 million at-the-market (ATM) equity sales agreement. According to the company's SEC 10-K filing, they did not sell any shares under this program through the end of 2025, leaving the full
$100 million in remaining capacity intact moving into recent quarters. However, they have recently chosen to use traditional structured underwritten public offerings to secure immediate cash.
The coming probable dilution is factored into the price and also into the price target of over
$9.
By the way, they have a good chance to get an FDA Rare Pediatric Disease Priority Review Voucher (PRV). This is a couple years away, but if they do get it they could sell it to a large pharmaceutical company for
$150 to
$200 million!
